IW 388

August 2, 2026 Viktor Zarev 0 min read
  1. FTC sues Hims & Hers over privacy and billing violations.
  2. VA to run GLP-1 trial for alcohol abuse.
  3. DR Congo Ebola epidemic becomes second largest.
  4. Labcorp sees strong medical testing demand.
  5. Cigna’s profits jump from employer-sponsored plans.
  6. NYC Legionnaires’ outbreak declared over.
  7. Judge rejects pausing Medicaid work requirements.
  8. Function gets $450M from General Catalyst.
  9. Alignment posts 32% increase in Q2 revenue.
  10. Siemens Healthineers & Cleveland Clinic form 10-year alliance.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions August 13, 2026

More Interventional Cardiologists, More Low-Value Stents August 13, 2026

The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.

Cardiology Business August 10, 2026

iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026

iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.

Cardiology Pharmaceuticals August 6, 2026

ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026

Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.